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Two prostaglandin endoperoxide H 2 synthase (PGHS) 1 isozymes, PGHS-1 and -2 (also known as cyclooxygenase-1 and -2, or COX-1 and COX-2), produce the intermediate PGH 2 from which prostaglandins, prostacyclin, and thromboxanes are derived. These two enzymes are both pharmacological targets of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) (1) . Recently, two new drugs have been developed, Celebrex and Vioxx, that selectively inhibit PGHS-2. These "COX-2 inhibitors" have an improved gastrointestinal safety profile, presumably because they do not interfere with prostaglandin production by PGHS-1 (2) . Preferential inhibition by COX-2 inhibitors results in part because these drugs are bulky and fit more readily in the larger active site of COX-2 (2, 3). However, the hallmark of COX-2 inhibitors is their differential mechanism of inhibition for PGHS-2. These drugs are time-dependent inhibitors of the PGHS-2, forming tight binding and slowly reversible complexes with this isozyme but are simple competitive reversible inhibitors of the PGHS-1 isozyme.
Formation of the NSAID-enzyme complexes has been proposed to result in conformational changes in PGHS (4) . This hypothesis is supported by studies that show that time-dependent inhibitors protect from proteolytic cleavage at Arg-277, 2 an amino acid located on a peptide loop distant from the inhibitor binding pocket (5) (6) (7) (8) . Competitive inhibitors also protect PGHS-1, but as might be expected, protection by these drugs is not as complete or long lasting as with time-dependent NSAIDs (8) . Heme, which binds at a site separate from the NSAID binding pocket, also protected PGHS from proteolysis, indicating a global flexibility in the enzymes.
Despite this circumstantial evidence that the PGHSs undergo conformational changes, comparisons of the x-ray crystal structure of PGHS-2 holoenzyme with the structures of PGHS-1 and PGHS-2 co-crystallized with various time-dependent NSAIDs reveals only minor structural differences. Amino acids 118 -122, helix D in the murine PGHS-2 membrane binding domain, have a decreased average B-factor in co-crystals with time-dependent inhibitors compared with the holoenzyme alone, indicating that NSAID binding reduces intrinsic flexibility in this region (9) . In the human PGHS-2, a 2.3-Å deflection of the side chain of Arg-106 3 as well as partial unwinding of the second half of helix D results from steric crowding following binding of the experimental NSAID RS57067 (10) . Other subtle structural changes are observed between various NSAIDbound forms of PGHS-2 (9), but none of the changes are of the magnitude or consistency to provide a general mechanism for proteolytic protection or time-dependent inhibition.
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EPR spectroscopy, we have examined arachidonate, NSAID, and heme-induced conformational changes of PGHS-2. Our measurements have allowed us to determine the inter-residue distances of side chains of amino acids located in the helices that form the opening of the cyclooxygenase active site and that also form the membrane binding domain for PGHS. The measurements have provided evidence for a structure of holo-PGHS-2 different from that obtained by x-ray analysis but that converts upon binding of arachidonate or time-dependent NSAIDs to a structure that appears identical to that obtained by x-ray analysis of the arachidonate-and NSAID-bound enzymes.
EXPERIMENTAL PROCEDURES
Materials-Pfu-Turbo polymerase was purchased from Stratagene. Nickel-nitrilotriacetic acid fast-flow resin was purchased from Qiagen. The EPR spin label 1-oxyl-2,2,5,5-tetramethylpyrroline-3 methyl methanethiosulfonate (MTSSL) was purchased from Reanal Fine Chemical (Budapest, Hungary) and was dissolved in acetonitrile at 10 mg/ml. Arachidonic acid was purchased from Cayman Chemical, and the inhibitor flurbiprofen was purchased from Sigma. C 10 E 6 was obtained from Anatrace. Cobalt-protoporphyrin IX was obtained from Porphyrin Products Inc. (Logan, UT). The COX-2-selective inhibitor SC-58125 was obtained from Karen Seibert at Searle. All DNA-modifying enzymes were obtained from New England Biolabs, and other chemicals were obtained from Sigma.
Site-directed Mutagenesis-A histidine-tagged version of the human PGHS-2 protein (11) was subcloned into the pFastbac plasmid and used for all experiments. All of the PGHS-2 mutants were synthesized by the Quick Change mutagenesis method (Stratagene) using complementary 30 -40 nucleotide long primers containing the desired mutations. Recombinant baculovirus expressing the mutant PGHS-2 proteins were generated using the Bac-to-Bac system from Life Technologies, Inc.
Expression and Purification of Recombinant PGHS Protein in SF21 Insect Cells-Sf21 Spodoptera cells were cultured in HyQ serum-free insect cell media (HyClone) to a cell density of 1.5-2 million cells/ml. Recombinant baculovirus particles were added at a multiplicity of infection of 0.01, and the infection was allowed to proceed for 72-96 h. (11) . Cells were harvested and washed with phosphate-buffered saline, and the cell pellets were stored at Ϫ80°C.
PGHS protein was purified from the SF21 cell pellets using methods described previously (11) . Briefly, the insect cell pellet was resuspended in 3 ml of nickel purification buffer (25 mM NaPO 4 , pH 7.4, containing 100 mM NaCl and 20 mM imidazole) per g wet weight of cells. All purification buffers used were degassed and sparged with argon gas. Cells were lysed by sonication, and the protein was solubilized by adding C 10 E 6 to a final concentration of 1% (v/v). Insoluble material was removed by centrifugation at 100,000 ϫ g for 30 min, and the solubilized protein was incubated with shaking with Fast-flow nickel-nitrilotriacetic acid resin for 1 h. The resin was then poured into a column, washed consecutively with 5 column volumes of nickel purification buffer containing 0.1% C 10 E 6 followed by 5 column volumes of nickel wash buffer (25 mM NaPO 4 , pH 7.4, containing 100 mM NaCl and 20 mM imidazole with 0.1% C 10 E 6 ) prior to elution with 5 column volumes of nickel elution buffer (25 mM NaPO 4 , pH 7.4, containing 300 mM NaCl, 200 mM imidazole, and 0.1% C 10 E 6 ).
Site-directed Spin Labeling-Purified PGHS mutant protein was concentrated to approximately 4 mg/ml using Millipore Ultrafree Centrifugal concentrators. The protein was next passed over two G-25 Sephadex spin columns equilibrated with labeling buffer (25 mM TrisCl, pH 7.7, 50 mM KCl, 0.1% C 10 E 6 ). The buffer exchanged protein was incubated overnight on ice with 100 molar equivalents of MTSSL. The derivatized protein was next passed over three 3-ml G-25 Sephadex spin columns equilibrated with labeling buffer to remove unbound MTSSL. Analysis of the dipolar broadening function (in Fourier space) indicated that between 60 and 90% of the proteins were doubly labeled, in other words that 10 -40% were monoradical species. (12) . It has been demonstrated that accurate inter-nitroxide distance calculations can be obtained from populations containing as little as 40% doubly labeled proteins using the Fourier deconvolution technique when spectra are collected at low temperatures (13) (see below). For most experiments, the PGHS protein was next reconstituted with either 5 molar equivalents of Fe 3ϩ protoporphyrin IX (hemin) or Co 3ϩ protoporphyrin IX. Flurbiprofen or SC-58125 were incubated with hemin-reconstituted protein for 10 min on ice before freezing at 183 K. Arachidonic acid was incubated with the cobalt-reconstituted protein for 10 min on ice before freezing at 183 K.
EPR Data Collection-X-band EPR spectra of the labeled protein were collected using a Bruker ESP-300e spectrometer at 183 K with a Bruker ST9234 box cavity resonator. Low temperature measurements were employed to minimize the effects due to variability in spin label coupling efficiency as well as to minimize the exchange interactions, dynamic and static magnetic dipolar interactions, and the effects of molecular tumbling that complicate the calculation of distances using spectral broadening (12) . Data were collected from 3320 to 3420 G. The center point of the nitroxide spectra was located at 3368 G. All spectra were measured using 10 milliwatts of microwave power with a modulation amplitude of 2 G. Ten scans were signal-averaged for each spectra.
Calculation of Inter-nitroxide Distances-Fourier transform/deconvolution analysis of the broadening functions resulting from spin-spin interactions of the dually labeled PGSH-2 was used to calculate the molecular distance between the nitroxides by comparing the broadening of the doubly labeled proteins to the singly labeled reference spectra using scripts written for Matlab® (14) . Theoretically, individual double label spectra should be compared with the sum of corresponding single label spectra as there are small variations of g-and A-tensors due to the local polarity of the nitroxide environment, leading to small changes in EPR spectra. However, it has been found from extensive model calculations that the distances obtained from the Fourier analysis have little dependence on the choice of the reference spectrum. 4 In this study, we have chosen spectra of the Cys-74 and Cys-88 single mutants as our reference spectra. For the arachidonate complexes, Co-heme-reconstituted single mutant spectra of Cys-74 and Cys-88 were used for reference. The distances obtained using these two reference spectra were essentially the same.
Estimating Inter-nitroxide Distances from X-ray Crystal StructuresThe coordinates for the x-ray structures of the murine holo-PGHS-2 (5COX) and the flurbiprofen (3PGH) and SC-558 (6COX) complexes of the murine PGHS-2 enzymes were obtained from the Protein Data Bank and were originally reported by Kurumbail et al. (9) . The coordinates for the ovine PGHS-1 structure complexed with arachidonate (1DIY) were obtained from Dr. Michael Garavito (see Ref. 15) . To compare the inter-nitroxide distances obtained by our EPR measurements with the inter-residue distances obtained from the coordinates of their cognate crystal structures, we first modeled cysteinyl-nitroxides onto the corresponding x-ray structures using the Insight II (MSI) molecular modeling software. Side chains of the amino acid residues mutated to cysteines for the EPR studies were changed to cysteines in the coordinate files, and the MTSSL label was modeled onto the residues. The arm lengths from the ␣-carbon of the peptide backbone to the nitroxide on the label were constrained at 6.8 Å as described previously (14) . A 1000 step energy minimization calculation was then performed for each nitroxide pair for each set of coordinates using the Discover molecular dynamics module of Insight II, and energetically favorable conformations for each pair of MTSSL moieties were obtained. The steepest decent and gradient descent energy minimization protocols each gave similar side chain orientations. This process was repeated for each of the 10 pairs of mutants analyzed by EPR using coordinates for the murine holo-PGHS-2 (5COX), the flurbiprofen (3PGH), and SC-558 (6COX) complexes of the murine PGHS-2 and the ovine PGHS-1 crystallized with arachidonate (1DIY). From the energy-minimized models, the distances between the nitroxides of the MTSSL label were determined, and these values were compared with those determined experimentally by Fourier deconvolution analysis of the EPR spectra.
Generating a Structural Model of Solubilized PGHS-2 Holoenzyme from EPR Data-The inter-helical distances obtained for the nitroxide residues in the PGHS-2 holoenzyme from EPR analysis were used to construct a model membrane binding domain of the solubilized PGHS-2 holoenzyme using a two-step process. Inter-residue distances of the native amino acids were required to construct a model of the solubilized holoenzyme; however, only inter-nitroxide distances were determined in the EPR experiments. Although the ␤-carbon distances should be nearly identical for nitroxide-derivatized and the native amino acids, the ␤-carbon distances are not easily calculated directly from the nitroxide distances. Thus, we first modeled the nitroxide residues into the appropriate PGHS-2 structure, fixed the inter-nitroxide distances based on our EPR measurements, and then determined the ␤-carbon distances, which were in turn used to constrain the distances for model building. Each nitroxide-conjugated cysteine pair was individually modeled into the backbone of the murine PGHS-2 holoenzyme complex (5COX) using the Insight II (MSI) modeling software. The distance from the ␣-carbon of each amino acid to the nitroxide was constrained at 6.8 Å (14) , and the distances between the nitroxide pairs were constrained to the values determined from the EPR analysis. A 1000 step energy minimization calculation was conducted using the Discover module of the Insight II suite of molecular modeling programs. This process was repeated for each pair of mutants to determine the distances between the ␤-carbon of residue 98 and the ␤-carbon of each of the corresponding spin-labeled amino acids in helix B or C. Minimizations were repeated in triplicate for each pair of substitutions; the results were consistent to within Ϯ 0.4 Å. Next, the ␤-carbon distances obtained from these initial minimizations were used to constrain the distances of the native amino acids, and a final 1000 step energy minimization calculation was performed using the coordinates of the entire murine PGHS-2 holoenzyme (5COX). The resulting model of the membrane binding domain is a best approximation structure that has inter-residue distances consistent with those determined in our EPR measurements.
RESULTS
The technique of site-directed spin labeling requires a template cDNA that does not contain reactive cysteines; cysteine substitutions are then made at selected sites, and the resulting mutants are coupled with a sulfhydryl-reactive nitroxide-containing reagent to incorporate paramagnetic spin labels (16) . A "cysteine-less" template was prepared by mutating cysteines at positions 299 and 526 in the human histidine-tagged enzyme PGHS-2 (11). The cysteine-less enzyme retains 70% of the cyclooxygenase and peroxidase activities of the native Histagged PGHS-2 ( Table I ), indicating that cysteines 299 and 526 are not required for catalysis and that these substitutions only minimally distort the structure of the protein.
Four helices (A-D) form the membrane binding domain which is also the mouth of the cyclooxygenase active site (17) . These helices were chosen as labeling sites because this is the region where the most flexibility is observed in crystal structures of PGHS (9, 10) . By using the cysteine-less template, 10 mutants were constructed, each containing the I98C substitution in helix D, and one of five amino acids substitutions in opposing helix B (T73C, V74C, H75C, Y76C, and I77C) or one of five amino acid substitutions in the adjacent helix C (F84C, W85C, N86C, V87C, and V88C) ( Fig. 1 and Table I ). No mutants were constructed with helix A which is located at the . Spectra were normalized to maximum absorbance and are uncorrected for any contribution by monoradical species. The EPR spectra were taken at 183 K; the x axis is H (gauss), and the y axis is arbitrary absorbance units. a Peroxidase activity determined by spectrophotometric assay as described previously (11) on nickel affinity chromatography purified enzyme before conjugation with MTSSL. All activities are normalized to the specific activity of the His-tagged native PGHS-2 protein purified as described under "Experimental Procedures."
b Cyclooxygenase activity determined by oxygen electrode as described previously (11) on nickel affinity chromatography purified enzyme before and after conjugation with MTSSL. All activities are normalized to the specific activity of the His-tagged native PGHS-2 protein purified as described under "Experimental Procedures." c NA, not applicable. d Cys Ϫ , human PGHS-2 mutant in which cysteines at positions 299 and 526 were substituted with serines. e Numbering corresponds to human PGHS-2 (25) . Mutants contain cysteine substitutions at the indicated amino acids.
interface of the PGHS homodimer, as spin-spin coupling could occur between subunits confounding any measurements of inter-helix spin-spin coupling.
The histidine-tagged mutant proteins were expressed in sf-21 cells using baculovirus constructs and purified using nickel affinity chromatography as described previously (11) . Nine of ten double cysteine mutants retained significant cyclooxygenase and peroxidase activities (20 -70% of the native) ( Table I) . One mutation, W85C, reduced cyclooxygenase and peroxidase activity 95-98%, indicating that this residue plays a critical role in protein structure or catalysis. Conjugation of the cysteines with the spin label MTSSL had little or no additional effect on activity. These results demonstrated that with one exception, the cysteine substitutions and subsequent conjugation with the spin label do not grossly disrupt the native structure of the enzyme. Previous studies have also observed relatively few severe adverse effects on protein structure or function following modification with spin labels (16) . The near total loss of activity in the W85C mutant was accompanied by a lack of correlation between the inter-residue distances obtained by EPR with those obtained from the x-ray crystal structures (see below). These results were unique for the W85C mutant and are consistent with the conclusion that this mutation significantly alters PGHS-2 structure.
Each of the 10 pair-wise mutant proteins were purified and concentrated to 4 -5 mg/ml (Ϸ60 M) and then reconstituted with 5 molar equivalents of hemin. Time-dependent NSAID inhibitors were added to aliquots of each sample, and the EPR spectra of the holoenzyme and NSAID-treated enzymes were recorded at 183 K. The low temperature absorbance (integrated) spectra of the MTSSL-labeled V74C holoenzyme overlaid with the spectra of the Y76C/I98C holoenzyme and the Y76C/ I98C holoenzyme with flurbiprofen ( Fig. 2) illustrate the typical line broadening resulting from spin-spin coupling in double mutants. The spectra of the doubly labeled mutant narrowed upon addition of flurbiprofen, indicating that this NSAID increases the inter-nitroxide distances between residues 76 and 98. A comparison of the first derivative spectra obtained for the holoenzyme and the holoenzyme-flurbiprofen complexes (100 M) for each of the 10 double mutants are shown in Fig. 3A . The line shape of these spectra are similar to spectra of other proteins containing dual MTSSL nitroxide labels (12) . The major resonance peak is at 3368 G. Incubation with flurbiprofen potentiated and sharpened the EPR spectra of all labeled enzymes, although the effects are most evident in the V14C/ I98C, I77C/I98C, F84C/I98C, W85C/I98C, and N86C/I98C mutants. The increased amplitude and narrowing of the spectra result from reduced spin-spin interactions due to an increase in the inter-nitroxide distances. These results indicate that binding of flurbiprofen increases the inter-residue distances in the PGHS-2 membrane binding domain compared with the holoenzyme (Tables II and III) . Addition of the COX-2-selective inhibitor SC58125 (50 M) to the PGHS-2 holoenzyme resulted in a similar increase and narrowing of the main feature in the spectra (not shown) (Tables II and III) , suggesting that the observed increase in inter-residue distances is a general phenomena resulting from binding of time-dependent NSAIDs.
Co-PPIX was next used to reconstitute the 10 pair-wisesubstituted PGHS-2 mutants. Binding of Co-PPIX to PGHS is identical to hemin and does not alter the structure of the enzyme (15), nor does Co-PPIX produce an EPR signal (data not shown). However, the Co-PPIX PGHS-2 enzyme is inactive and thus can be used to examine the binding of fatty acid substrates such as arachidonate. Addition of arachidonate to the Co-PPIX-reconstituted PGHS-2 mutants resulted in a pattern of potentiation and sharpening of the EPR spectra similar to that observed with the flurbiprofen and SC58125 (data not shown), indicating that binding of arachidonate by PGHS-2 also leads to a general increase in the inter-residue distances between amino acid 98 in helix D and helices B and C.
In contrast, addition of hemin to the apoenzyme resulted in attenuation of the EPR signal and a broadening of the spectra (Fig. 3B) , effects that were opposite in direction but similar in magnitude to the changes observed upon addition of NSAIDs to the holoenzyme. Similar spectral changes were observed upon addition of the Co-PPIX (data not shown), indicating that the effects did not result from nonspecific interactions of heme with the paramagnetic nitroxides. The inter-residue distances obtained for the apoenzyme are similar to those determined for the flurbiprofen, SC58125, and arachidonate-bound enzymes (see below) (Table II) . Thus, addition of the heme appears to decrease the inter-helical distances, constricting the opening of the active site. Binding of flurbiprofen, SC58125, and arachidonate to the holo-PGHS reverses this effect by increasing the interhelical distances and widening the entrance to the cyclooxygenase active site.
To confirm that the observed spectral changes correlated with ligand binding and were not artifacts resulting from nonspecific interactions between ligands and nitroxides, we titrated the changes in inter-residue distances, as calculated from the broadening of the spectra, with the molar equivalence of ligands added to the PGHS-2 proteins. A Fourier deconvolution method that uses the spectral broadening resulting from spin-spin coupling was used to estimate the distances between nitroxide spin labels in the various pair-wise mutants (Table II) (14) . The relative change, calculated as the percent of maximum changes in distance with saturating ligand, increased linearly with increasing ligand, reaching a plateau at a 1:1 molar equivalent of heme, arachidonate, or flurbiprofen (Fig.  4) . Nearly identical curves were obtained with each of the ligands tested for the following three different pair-wise mutants: 77C/98C, 84C/98C, and 86C/98C (Fig. 4) . Because the concentration of enzyme required for EPR analysis (0.60 M) is higher than the K m value for arachidonate (Ϸ5 M) or IC 50 for flurbiprofen (0.4 M), it is not possible to determine binding curves using this method. Nevertheless, these experiments provide strong evidence that the spectral changes observed result from specific binding of the ligands.
Comparison of EPR and X-ray Crystal Structure Data-EPR spectra were collected from at least three different preparations of all 10 mutants for the apo-PGHS-2, the hemin-reconstituted PGHS-2 holoenzyme, the PGHS-2 holoenzyme complexed with flurbiprofen and SC58125, and the Co-PPIX PGHS-2 complexed with arachidonate. From the EPR spectra of these samples, the inter-nitroxide distances were calculated using Fourier deconvolution (Table II) (14) . Distances between nitroxide residues ranged from 6.8 to 18.7 Å. The average of the standard errors for our triplicate measurements was 0.78 Ϯ 0.46 Å (n ϭ 50). Rabenstein and Shin (14) found that the nitroxide distances determined for a series of synthetic cysteine-substituted polyalanine peptides calculated by Fourier deconvolution fit well with the theoretical distances calculated Fig. 3 . A, overlay of typical EPR spectra obtained from the 10 pair-wise substituted mutants for the PGHS-2 holoenzyme (blue) and the PGHS-flurbiprofen complex (red). Spectra were obtained on a Bruker ESP-300e spectrometer at 183 K as described under "Experimental Procedures" using a scan width of 100 G (3320-3420 G). The central nitroxide peak is at 3368 G. B, overlay EPR spectra of the 74/98 and 86/98 pair-wise mutant of the apo-PGHS-2 (red) and PGHS-2 holoenzyme (blue). Each pair of spectra are from identical aliquots of a single derivatized protein preparation with and without flurbiprofen.
based on the ␣-helical geometry of these helices with an S.D. of Ϯ 0.9 Å. This indicates that the variability in our measurements is near the expected limits of this method.
A direct comparison of the inter-nitroxide distances obtained from the EPR measurements of PGHS-2 with the distances between the corresponding amino acids in analogous crystal structures is complicated by the introduction of the bulky nitroxide side chains. Since the lengths of the nitroxide side chains are on average longer than that of the native side chains, the increased radial extension of the nitroxide-modified side chains from the ␣-helical cylinder must be taken into consideration when comparing the inter-residue distances of 
Comparison of inter-residue distances as determined by EPR spectroscopy and as calculated from the x-ray crystal structures
EPR distances between nitroxides were determined using Fourier deconvolution analysis (14) . All distance determinations were conducted on three or more EPR data sets. X-ray distances were determined using the cognate crystal structures as described under "Experimental Procedures." Ϫ0.4 a EPR spectroscopy was carried out with the purified PGHS-2, which is an apoenzyme free of heme.
b EPR spectroscopy was carried out with purified enzyme reconstituted with hemin; x-ray values were computed using the coordinates of the murine PGHS-2 holoenzyme (5COX) (9) .
c EPR spectroscopy was carried out with purified enzyme reconstituted with Co-PPIX and arachidonate; x-ray values were computed using the coordinates of the ovine PGHS-1-arachidonate complex (1DIY) (15) .
d
EPR spectroscopy was carried out with the purified PGHS-2 reconstituted with hemin and flurbiprofen; x-ray values were computed using the coordinates of the murine PGHS-2-flurbiprofen complex (3PGH) (9) .
e EPR spectroscopy was carried out with purified enzyme reconstituted with hemin and SC58125; x-ray values were computed using the coordinates of the murine PGHS-2-SC558 complex (6COX) (9) .
f All distances are in angstroms.
g Numbering corresponds to human PGHS-2 (25) . Mutants contain cysteine substitutions at the indicated amino acids.
FIG. 4.
A, binding curve showing the percent relative change in nitroxide distances between residues 77/98 (f), 84/98 (ࡗ), and 86/98 (OE) following reconstitution of the apo-PGHS-2 with heme. Increasing molar equivalents of hemin were added to the purified PGHS-2 and allowed to incubate on ice for 10 min prior to EPR analysis. Maximum changes in distances between the nitroxide side chain pairs 77/98, 84/98, and 86/98 were 2.0, 5.2, and 5.9 Å, respectively. B, binding curve showing the percent relative change in nitroxide distances between residues 76/98 (q), 77/98 (f), 84/98 (ࡗ), and 86/98 (OE) in the Co-PPIX reconstituted PGHS-2 following addition of arachidonate. Enzyme and arachidonate were allowed to incubate on ice for 10 min prior to EPR analysis. Maximal changes in distances between the side chain nitroxide pairs 76/98, 77/98, 84/98, and 86/98 in the Co-PPIX-reconstituted PGHS-2 following addition of arachidonate were 3.1, 2.0, 3.5, and 7.5 Å, respectively. C, binding curve showing the percent relative change in nitroxide distances between residues 76/98 (q), 77/98 (f), and 84/98 (ࡗ) in the hemin-reconstituted PGHS-2 holoenzyme following incubation with increasing molar equivalents of flurbiprofen. Enzyme and flurbiprofen were allowed to incubate on ice for 10 min prior to EPR analysis. Maximal changes in distances between the side chain nitroxide pairs 76/98, 77/98, and 84/98 in the hemin-reconstituted PGHS-2 following addition of flurbiprofen were 1.5, 2.0, 2.1 Å, respectively. All distances were determine by Fourier deconvolution analysis (14) . the nitroxide-conjugated side chains with the distances between the native amino acid side chains. In addition, the bulky nitroxides may orient within the protein differently than the native side chains. To simplify this problem, we assumed there is one most energetically favorable conformation for each nitroxide side chain, and we estimated the orientation of this conformation by modeling the MTSSL-conjugated cysteines into the corresponding amino acid side chain position of the appropriate PGHS crystal structures. By using coordinates for PGHS proteins deposited in the Protein Data Bank, molecular dynamic simulations were conducted using the Discover module of the Insight II suite of programs to determine the energetically most favorable conformation for each of the 10 nitroxide pairs in each crystal structure. After energy minimization, the inter-nitroxide distances were then determined from the resulting coordinates, and these were compared with the values calculated from the EPR analysis. The inter-residue distances obtained by EPR analysis of the human PGHS-2 holoenzyme, the human holoenzyme complexed with arachidonate, SC58125, and flurbiprofen were compared with the distances obtained by modeling nitroxides onto the x-ray coordinates of, respectively, the murine PGHS-2 holoenzyme (9), the murine PGHS-2 holoenzyme complexed with flurbiprofen, and SC-558 (closely related to SC58125, see Ref.
2) (9), and the arachidonate co-crystal of the Co-PPIX-reconstituted PGHS-1 (15) .
A close correlation was observed between the inter-residue distances determined experimentally by Fourier analysis of the EPR spectra and the distances obtained by modeling using the crystal structure coordinates of PGHS complexes with arachidonate, flurbiprofen, and SC558 (Table II) . The average absolute differences between the values obtained from the crystal structures and the EPR measurements for these three complexes was 0.703 Ϯ 0.35 Å, less than our average error for the measurements themselves (0.78 Ϯ 0.46 Å). The lack of activity of the 85C/98C mutant suggests that this enzyme does not have the native conformation, and the wide discrepancies between the EPR and modeling data (4 -5 Å) support this observation (Table II) . Thus, we have excluded the 85C/98C mutant values from our comparison.
In contrast to the three liganded PGHS-2 complexes, the holoenzyme shows a poor correlation between the EPR-determined inter-residue distances and those obtained from the crystal structure of the murine holo-PGHS-2. The absolute differences in these measurements, excluding the value for the 85C/98C mutant, is 3.1 Ϯ 1.5 Å, more than four times the average absolute difference seen with the three PGHS-2 complexes and four times the average variability of our measurements. The most likely explanation for the lack of correlation between values obtained for the holo-PGHS-2 by EPR with those obtained from the crystal structure is that solubilized PGHS-2 assumes a different conformation in solution than in crystals.
Ligand-induced Conformational Changes in PGHS-2-We next examined how the binding of arachidonate, NSAID inhibitors, and heme altered the conformation of the solubilized PGHS-2 holoenzyme (Table II) . Binding of arachidonate and both time-dependent inhibitors led to a general increase in the distances between helix D and helices B and C compared with the holoenzyme. This is most evident in the amino acids, which form the corner between helices B and C (Fig. 1) , amino acids 76 -77 (helix B), and 84 and 86 -87 (helix C). In this region, increases in inter-residue distances range from 1 to 7.9 Å with an average of 3.2 Å. (Again, the inactive W85C/I98C mutant was excluded from these calculations.) The inter-residue distances for three out of five amino acids at the helix B-C junction increase by 2 Å or more, indicating that binding of both arachidonate and inhibitors results in a significant bulging in this corner and likely partial unwinding of the helices (Fig. 5) .
The inter-residue distances calculated from the EPR spectra of the apoenzyme are similar to those of the ligand-bound holoenzyme (Table II) . Addition of heme to the apoenzyme leads to a reduction of the inter-residue distances and a general constriction of the opening to the cyclooxygenase site. Thus, the inter-residue distances between the membrane binding domain helices are similar for the apoenzyme and arachidonate-NSAID enzyme complexes. Overall, two general conformations of the PGHS-2 were observed as follows: a compact configuration in the holoenzyme in which the helices of the membrane binding domain are at their closest proximity, and a extended form in the ligand-bound holoenzyme and the apoenzyme in which the distances between the helices that compose the mouth of the cyclooxygenase active site increase about 3 Å.
DISCUSSION
The technique of site-directed spin labeling combined with EPR spectroscopy has proven particularly useful for probing the structural dynamics of membrane proteins such as rhodopsin (18) and more recently the Streptomyces potassium channel (19, 20) . For the present experiments, EPR spectroscopy was used to examine a set of 10 pair-wise labeled PGHS-2 mutants to determine whether conformational changes occur in the human PGHS-2 enzyme following binding arachidonate, NSAIDs, and heme. The membrane binding domain of PGHS-2 was selected for study because these four helices make up the opening and lower extremity of the cyclooxygenase active site, the area where the most pronounced variability in structure has been observed between PGHS structures co-crystallized with different NSAIDs (9, 10) . Arachidonate and time-dependent inhibitors potentiated the signal and sharpened the main feature in the EPR spectra of the 10 different pair-wise mutants of PGHS-2 indicating that binding of these ligands resulted in a general increase in the relative inter-residue distances between helix D and helices B and C. This was unexpected as previous comparisons of the x-ray structures of the holoenzyme and NSAID bound forms of PGHS-2 had indicated only subtle differences in their structures (9) . Binding of heme to the apoenzyme had an opposite effect, decreasing the average distances between these same helices. Titration curves showed that the maximal increase or decrease in inter-nitroxide distances occurred with a 1:1 molar ratio of PGHS-2 to ligand, indicating the changes are due to specific binding and not to nonspecific interaction of the ligands with the nitroxides (Fig. 3) .
The absolute distances between the nitroxide pairs in the holoenzyme and ligand-bound PGHS-2 were determined by a Fourier deconvolution analysis of the broadening of the EPR spectra, a method that has been validated using model ␣-helical peptides (14) ( Table II) . The inter-residue distances calculated for arachidonate, flurbiprofen, and SC58125-bound PGHS-2 correlated well with the distances obtained by modeling cysteinyl-nitroxides residues into the appropriate amino acid positions of the most closely corresponding crystal structures (Table III) . The mean differences between the distances obtained from the x-ray crystal coordinates and from the EPR spectroscopy for the flurbiprofen, SC58125, and arachidonatebound PGHS-2 were 0.703 Ϯ 0.35 Å, about the same as the variability in our measurements (0.78 Ϯ 0.46 Å). Thus, to the limits of this method, the inter-chain distances calculated by the EPR spectroscopy for the three ligand-bound forms of the PGHS-2 are identical to those obtained from the crystal structures. This concordance is remarkable when considering that the murine PGSH-2 crystal structures of the flurbiprofen and SC558 complexes were compared with the EPR values obtained from the flurbiprofen and SC58125 complexes of the human PGHS-2 and that the crystal structures of the ovine PGHS-1 Co-PPIX arachidonate complex were compared with the EPR values obtained from the Co-PPIX arachidonate human PGHS-2 complex. The close correlation by these two methods provides strong evidence that the values obtained from the EPR measurement accurately represent the conformations of the solubilized PGHS-2.
The distinct conformational changes detected by EPR analysis following arachidonate and NSAID binding imply that the holoenzyme and ligand-bound forms of solubilized PGHS-2 must be structurally distinct. Furthermore, since the crystal structures of holoenzyme and ligand-bound PGHS are nearly identical (9), the structure of solubilized holo-PGHS-2 as determined by EPR must differ from that of the crystalline form of the PGHS holoenzyme as determined by x-ray analysis. In fact, the distances between the amino acid pairs determined for the solubilized holo-PGHS-2 by EPR were an average 3.1 Ϯ 1.5 Å shorter than those calculated from the x-ray coordinates. Thus, one of the most novel findings of these studies is that ligandless PGHS-2 holoenzyme has a profoundly different structure from that reported for murine PGHS-2 holoenzyme using x-ray crystallographic techniques (9) . The best evidence that the EPR spectra structure of the holoenzyme is correct and not simply an artifact of the spin-labeling technique is the nearly perfect agreement for the distances obtained for the arachidonate, a Changes in the inter-residue distances as determined by EPR spectroscopy for the hemin-reconstituted PGHS-2 holoenzyme as compared with the PGHS-2 apoenzyme.
b Changes in the inter-residue distances determined by EPR spectroscopy for the hemin-reconstituted PGHS-2 holoenzyme as compared with the PGHS-2 reconstituted with Co-PPIX and arachidonate.
c Changes in the inter-residue distances determined by EPR spectroscopy for the hemin-reconstituted PGHS-2 as compared with the PGHS-2 reconstituted with hemin and flurbiprofen.
d Changes in the inter-residue distances determined by EPR spectroscopy for the hemin-reconstituted PGHS-2 holoenzyme as compared with the PGHS-2 reconstituted with hemin and SC58125.
e Numbering corresponds to human PGHS-2 (25) . Mutants contain cysteine substitutions at the indicated amino acids.
flurbiprofen, and SC58125 forms of PGHS-2 by EPR with the distances calculated from their cognate crystal structures. One likely explanation as to why the crystal structure of the holoenzyme is different than the structure we observed is that an equilibrium exists between different conformations of the solubilized PGHS and only one of these forms readily crystallizes. Although solubilized holo-PGHS-2 can adopt a crystallizable conformation, this structure is not the favored structure and thus is not the structure observed when making the EPR measurements. Binding of NSAIDs would shift this equilibrium toward the most favored conformation for crystallization, which would explain why PGHS-NSAID co-crystals are more readily obtained and possibly why the resolution of the one holoenzyme structure is so poor (9) . At least one other example has been reported where the solution structure differs markedly from the x-ray analysis (21, 22) . The solution structures of palindromic double-stranded oligomers that contain base pair mismatches determined by NMR spectroscopy show that the non-complementary base pairs are incorporated within the helix by introducing kinks that disrupt the DNA-B conformation. In the crystal structure, however, the DNA-B conformation is maintained, presumably because it crystallizes more readily, and the mismatched bases flip to the exterior of the helix.
Probably the most significant implication of the newly observed structure of solubilized unbound PGHS-2 is that it provides direct evidence that binding of the substrate arachidonate induces a structural change in the enzyme. The finding was completely unanticipated and may have significant implications about the catalytic mechanism of this enzyme. A model for the structure of the membrane binding domain of the holo-PGHS-2 consistent with our EPR measurements is presented in Fig. 5 . This model was constructed using coordinates of the x-ray structure of the unliganded murine PGHS-2 (PGS3) (9) . The inter-residue distances were constrained to those determined spectroscopically, and molecular dynamic simulation was performed to find an energy-favored conformation. The model obtained indicates that differences between the unliganded and arachidonate/NSAID-bound enzyme result from both rigid helix movements and from radial displacement of the individual side chains due to unwinding or winding of the helices. Binding of arachidonate or NSAID move helix B down and away from helix D, whereas the helix formed by the first few residues of helix C (amino acids 84 -86) unwinds, moving the side chains on this end of helix C farther from helix D. It is likely that flexibility in the loop connecting helices B and C allows for this movement. The mouth of the active site of the NSAID-bound enzyme appears to be wider than the unbound enzyme, which may result because arachidonate and NSAIDs prop open the active site.
The results of the EPR measurements also indicate that binding of heme by the apoenzyme results in structural changes in the membrane-binding helices of the same magnitude as seen with arachidonate and NSAIDs, although opposite in direction. The fact that heme, which binds to a site distant and separate from the NSAID pocket, can produce structural movements proportional to those induced by NSAIDS indicates that the transitions we have observed are not localized solely to the membrane binding domain and cyclooxygenase active site but are global. In previous studies, both heme and indomethacin were found to protect PGHS-1 from proteolysis at the trypsin cleavage site (Arg-277) 2 located on the exterior of this isozyme, which is consistent with our observation that both NSAIDs and heme induce structural changes. These results suggest that these distal protein sequences are interconnected. It thus seems likely that the structural changes we measured in the membrane binding domain result from the reciprocal movement of residues in the heme-and substrate-binding sites.
Oxygenation of arachidonate proceeds by a free radical mechanism, and thus precise positioning of arachidonate in the active site is essential for efficient production of prostaglandin G 2 . Alternative products are obtained when mutations within the active site alter substrate orientation (23) . The conformational change in PGHS-2 that we observed upon arachidonate binding may be a mechanism that signals when the substrate is properly positioned within the cyclooxygenase site. This arachidonate/enzyme conformation is likely stabilized by formation of the same network of hydrogen bonds between amino acid side chains at the mouth of the cyclooxygenase active site that stabilizes binding of time-dependent inhibitors (24) . Following oxygenation, a conformational rearrangement of arachidonate occurs (15) that could disrupt this hydrogen-bonding network leading to release of prostaglandin G 2 . Since time-dependent NSAIDs cannot undergo oxygenation, the unproductive hydrogen bond-stabilized complex they form dissociates only slowly (24) . Thus, time-dependent inhibition may be a serendipitous outcome of a catalytic mechanism evolved in PGHS to ensure fidelity of the cyclooxygenase reaction.
